In recent years, genome-wide association studies (GWAS) have identified many different genetic variants associated with schizophrenia. These genetic discoveries raise the promise of developing urgently needed new treatments targeting the underlying biology and pathophysiology of schizophrenia, according to a special article in the Journal of Clinical Psychopharmacology. The journal is published in the Lippincott portfolio by Wolters Kluwer.
- Farmers in developing countries can protect both profits and endangered species
- Scientists use Doppler to peer inside cells
- New sustainable building simulation method points to the future of design
- Urban Americans more likely to follow covid-19 prevention behaviors than rural Americans
- Signal transduction without signal — receptor clusters can direct cell movement